Healthcare administrative (claims) data are commonly utilized to estimate drug effects. We
identified considerable heterogeneity in fracture outcome definitions in a scoping review of …

Background: An osteoporosis drug holiday is recommended for most patients after 3 to 5
years of therapy. Risedronate has a shorter half-life than alendronate, and thus the residual …

Persistence to denosumab or zoledronic acid was increased compared to oral
bisphosphonates. Introduction Denosumab and zoledronic acid are alternative therapies to …

Characteristics of patients starting oral bisphosphonate therapy changed over time,
reflecting trends in osteoporosis management (eg, new drugs to market), and general …

Objective During menopause, lower levels of estrogen may induce bone resorption as well
as anxiety and depression. Bisphosphonates represent the first choice in the treatment of …

Observational studies of osteoporosis medications can provide critical real-world evidence
(RWE) that fills knowledge gaps left by clinical trials. However, careful consideration of study …

Background Several different classes of medications have been shown to be efficacious at
preventing fractures in patients with osteoporosis. No study has compared real world …

Abstract Analysis of new user cohort studies of adverse drug effects can be based on either
intention-to-treat or as-treated paradigms. In the latter case, controlling for time-dependent …

Aim: To examine the performance of the disease risk score (DRS) in a cohort study with
evidence of policy-induced selection bias. Methods: We examined two cohorts of new users …

目的: 采用有限元方法动态分析亚洲型股骨近端防旋髓内钉(PFNA-Ⅱ) 治疗不稳定型股骨转子间
骨折后不同阶段的生物力学性能, 为临床上合理使用PFNA-Ⅱ 提供理论依据. 方法建立PFNA-Ⅱ …